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Nocturnal intermittent hypoxia (IH) featuring obstructive sleep apnea (OSA) dysregulates
hepatic lipid metabolism and might contribute to the development of non-alcoholic fatty
liver disease (NAFLD) observed in OSA patients. However, further research is required
to better understanding the molecular mechanisms underlying IH-induced hepatic lipid
accumulation. Therefore, the aim of the present study was to determine the effects of
OSA on hepatic CD36 expression and the impact of IH by using a mouse model of OSA.
Histological analysis, lipid content and CD36 expression were assessed in livers from
subjects who underwent liver biopsy and polygraphic study during sleep, and in livers
from mice submitted to chronic IH mimicking OSA. Among those who presented OSA
features, NAFLD were significantly more frequent than in control subjects with normal
respiratory function (77.8 vs. 36.4%, respectively), and showedmore severe liver disease.
Interestingly, CD36 expression was significantly overexpressed within the liver of OSA
patients with respect to controls, and a significant positive correlation was observed
between hepatic levels of CD36 and the values of two well-known respiratory parameters
that characterized OSA: apnea/hypopnea index (AHI) and oxygen desaturation index
(ODI). Moreover, hepatic lipid accumulation as well as induction of hepatic lipogenic
genes, and CD36 mRNA and protein expression were significantly higher in livers from
mice exposed to IH conditions for 8 weeks than in their corresponding littermates. This
study provides novel evidence that IH featuring OSA could contribute to NAFLD setup
partly by upregulating hepatic CD36 expression.
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is characterized by metabolic dysfunction and
accumulation of lipid deposits in the livers of patients in whom alcohol abuse is not the causal
agent of disease onset (1). NAFLD encompasses a wide range of histologic findings from simple
steatosis to non-alcoholic steatohepatitis (NASH) with fibrosis and, ultimately, liver cirrhosis, and
hepatocellular carcinoma (2). The number of individuals affected by some clinical form of this
chronic liver disease is steadily increasing because NAFLD is highly associated with obesity and
type 2 diabetes, being considered the hepatic manifestation of the metabolic syndrome (3).
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It is well-known that the liver maintains bodily lipid
homeostasis by regulating hepatic free fatty acid (FFA) uptake,
lipid synthesis, lipid oxidation, and lipid export; however, an
imbalance between these metabolic pathways can lead to an
excessive lipid accumulation within the liver (4), being an
increased de novo lipogenesis and largely an enhanced uptake
of FFAs released from insulin resistant-adipocytes the main
sources of these lipid accumulates (5). The uptake of FFAs into
hepatocytes is mainly dependent on the fatty acid translocase
CD36 which, under physiological conditions, is weakly expressed
in the liver and its expression increases by a number of different
stimuli, such as insulin and lipid metabolites, facilitating the
process of FFA uptake (6). Some experimental studies have
demonstrated that CD36 plays an important role inNAFLD setup
in rodents (7, 8) and, reinforcing this notion, it has been observed
that fatty liver attenuates in mice fed high fat diet (HFD) upon
either systemic or hepatocyte-specific deletion of CD36 (9, 10).
Moreover, a growing clinical evidence suggests that this FFA
transporter could play a relevant role in NAFLD pathogenesis in
humans as well. In particular, Greco et al. showed that hepatic
CD36 mRNA levels correlated with liver fat content in morbidly
obese patients (11). In addition, different clinical studies have
convincingly shown that the amount of both CD36 mRNA and
protein was higher in the livers of biopsy-provenNAFLD patients
than in subjects with histologically normal liver (12–14).
An increasing number of clinical studies point out to
a potential link between obstructive sleep apnea (OSA), a
respiratory disorder featured by nocturnal intermittent hypoxia
(IH) and sleep fragmentation, and NAFLD (15–18). To highlight,
both OSA and NAFLD are especially prevalent among obese
individuals and, more interestingly, the severity of nocturnal IH
positively correlates with histological features of NASH in OSA
patients (19). Although the underlying molecular mechanisms
are not fully understood, it has been reported that IH exacerbated
fatty liver in obese mice by inducing hepatic lipid biosynthesis
(20) likely due to the upregulation of the HIF1α/SREBP1c
signaling pathway (21), and that promoted liver inflammation
and fibrosis in mice fed with a HFD (22). However, further
research is required to unveil the pathophysiological interplays
between IH and lipid accumulation. In that regard, whether IH is
able to regulate CD36 gene expression in hepatocytes still remains
to be elucidated.
Therefore, the primary objective of this study was to
determine the impact of IH on CD36 expression as well as on
lipid content in livers from OSA patients with biopsy-proven
NAFLD and in livers from mice exposed to IH.
MATERIALS AND METHODS
Patients
This study was performed in agreement with the Declaration
of Helsinki, and with local and national laws. The Human
Ethics Committee of the Hospital Universitario Santa Cristina
(HUSC, Madrid, Spain) approved all procedures (PI-688A).
This cross-sectional study included 20 patients with gallstones
to whom a programmed laparoscopic cholecystectomy was
performed in the HUSC. All participants gave a written consent
for a perioperative liver biopsy and a postoperative respiratory
polygraphy as part of an experimental protocol designed to
evaluate the relationship between sleep disturbances and liver
disease. All subjects included drank <20 g/day of alcohol, had
no previous respiratory disorders, were not having potentially
hepatotoxic drugs, had no analytical evidence of iron overload,
and were seronegative for autoantibodies, for hepatitis B virus,
hepatitis C virus, and human immunodeficiency virus.
Sleep Study
The polygraphic studies were performed at night in the Sleep
Laboratory of the HUSC (Madrid, Spain). For interpretation,
the recommendations of the American Academy of Sleep
Medicine (AASM) for the diagnosis of OSA were followed. The
apnea/hypopnea index (AHI) was used as diagnostic criteria
for severity of OSA: AHI < 5, no OSA; AHI 5–14, mild
OSA; AHI 15–29, moderate OSA; AHI ≥30, severe OSA. In
addition, nocturnal hypoxemia parameters including oxygen
desaturation index (ODI), cumulative sleep time percentage with
oxyhemoglobin saturation (SpO2) < 90% (Tc90) and minimum
SpO2 were analyzed.
Animal Care and Intermittent Hypoxia
Protocol
Twelve-weeks-old C57BL/6J mice were purchased from Charles
River Laboratories (Saint Germain sur L’Arbresle, France) and
divided into two groups of 10 mice. The control mice (C mice)
were placed in conditions of normoxia while the experimental
group (IH mice) was subjected to IH conditions. Every minute,
IHmice received air containing an oxygen fraction of 5% for 20 s,
followed by 40 s of room air, during 6 h per day, 5 days a week
for a total of 8 weeks. Control mice were only exposed to room
air (23). At the end of the experiment, mice were anesthetized,
sacrificed and livers were harvested. All experimental procedures
were approved by the Ethical Committee of the University of
Barcelona (174/18−10268).
Histopathology Assessment
Liver sections (5µm) were embedded in paraffin and cut
using a Microm microtome (Midland, ON, Canada). After
cutting, sections were stained with hematoxylin (1.09235.0500,
PanReac AppliChem, Barcelona, Spain) and eosin (71211,
Thermo Fisher Scientific, Inc., Madrid, Spain) and with Masson’s
Trichrome Solution (Masson Trichome Kit with Aniline Blue
04-010802, Milan, Italy). Once stained, the severity of steatosis
was quantified by a single-blind hepatopathologist. Specifically,
Kleiner’s histological scoring system was employed to evaluate
the degree of steatosis, lobular inflammation, hepatocellular
ballooning, and the stage of fibrosis (24). The following
percentages of steatotic hepatocytes were used in the histological
assessment: 0–5% hepatocytes, grade 0; 5–33%, grade 1; 33–
66%, grade 2; and >66%, grade 3. Histologic diagnosis of liver
biopsies was classified into two groups: simple steatosis without
hepatocellular ballooning nor lobular inflammation, also termed
NAFL, and NASH. Minimal criteria for NASH included the
combined presence of grade 1 steatosis, lobular inflammation
and hepatocellular ballooning with or without fibrosis. NAFLD
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activity score was also calculated for each liver biopsy (24). To this
end, three different lobular areas were analyzed in each sample.
Representative images were taken using a Nikon Eclipse E400
optical microscope (Nikon, Tokyo, Japan) and the NIS Elements
Imaging Software (Melville, NY, USA).
Assessment of Lipid Accumulation
Liver tissue was embedded in Tissue-Tek R© O.C.T.TM Compound
(Sakura Finetek Europe, Netherlands). Sections (10µm) were
then cut using a Leica CM1510S cryostat (Leica Microsistemas
S.L.U, Barcelona, Spain), stained using an Oil Red O biological
stain (Sigma-Aldrich, St. Louis, MO, USA) working solution
(60% ORO/isopropanol w:v), and counterstained with
hematoxylin (1.09235.0500, PanReac AppliChem). Three
different lobular areas were analyzed in each sample and
photographed using a Nikon Eclipse E400 optical microscope
(Nikon) and the NIS Elements Imaging Software (Melville).
Intensity of red stain was quantified using ImageJ Biological
Image Analysis (NIH) and reported as the average value in
arbitrary units (a.u.).
Quantitative Analysis of Hepatic
Triglycerides
Triglycerides (TGs) were extracted as described previously (25).
Briefly, liver biopsy samples (15–20 µg) were homogenized in
distilled water. Chloroform (−20◦C) and methanol (−20◦C)
were added to each sample. Samples were centrifuged and
the triglyceride-containing layer was collected. Once purified,
TGs were suspended in isopropanol and analyzed using
a colorimetric kit (SpinReact, Girona, Spain). Absorbance
values were obtained using a Dynex Spectra MR Microplate
spectrophotometer/computer software (Chantilly, VA, USA) and
graphically expressed as mg/dl.
Protein Extraction and Western Blot
Analysis
Liver biopsy samples (15–20 µg) were homogenized in an
extraction buffer containing the following: 10mM ethylene-
diamine-tetraacetic acid (EDTA), 50mM Hepes, 50mM sodium
pyrophosphate, 0.1mM NaF, 10mM Na3VO4, 1% Triton X-
100 and protease inhibitors. Protein extracts were stored at
−80◦C after centrifugation. A small aliquot of sample was
used for protein quantification (Bradford method). The samples
were then prepared to be loaded into 8% SDS-PAGE gels.
After running, proteins were further transferred to Inmunoblot
nitrocellulose membranes (BioRad Inc., Madrid, Spain), blocked
with 5% non-fat dry milk and incubated overnight with primary
antibodies: CD36/SR-B3 (1:1000, NB400-144, Novus Biotechne,
Abingdon, United Kingdom) and anti-βactin (1:5000, A-5441,
Sigma Aldrich). Then, the corresponding secondary antibodies
were added (Santa Cruz Biotechnology Inc., Heidelberg,
Germany). Using the Bio-Rad ClarityTM Western ECL Substrate
(BioRad Inc.), the immunoreactive bands were visualized by the
ImageQuant LASD 4000 digital imaging system (GE Healthcare
Europe, Barcelona, Spain). Densitometric analysis of the band
was performed using ImageJ Biological Image Analysis (NIH),
normalized against the loading control (βactin), and graphically
expressed as fold change relative to control condition (1).
Quantitative Real-Time PCR (RT-qPCR)
RNAwas extracted from liver samples using the TRIzol R© reagent
(Vitro, Sevilla, Spain). Samples were then reverse transcribed
using the Reverse Transcription System kit (Promega Inc.,
Madison, WI, USA). A BioRad T100TM Thermal Cycler was
used to carry out the reverse transcription. Quantitative real-
time polymerase chain reaction (RT-qPCR) was performed
to assess gene expression using a StepOnePlusTM Real Time
PCR System Sequence Detector (Thermo Fisher Scientific Inc.).
Samples were prepared using a SYBER Green qPCR Kit
(Promega Inc.) and d(N)6 random primers were purchased
from Metabion (Planegg, Germany). Primer sequences are
detailed in Supplementary Table 1. Each sample was run in
duplicated, normalized in comparison to 36B4 gene expression,
and graphically expressed as fold change relative to control
condition (1).
CD36 Immunohistochemistry
Paraffin-embedded liver biopsy sections (5µm) were
deparaffinized and rehydrated. Sections were then placed
in antigen retrieval buffer (10mM sodium citrate, pH 6–7),
boiled for 20min at 95◦C and incubated with a blocking solution
for 1 h before being immunostained with the CD36 antibody
(1:200, NB400-144, Novus) for 16 h in a moisture chamber. The
EnVisionTM FLEX Mini Kit, High pH (Link) (Agilent, Santa
Clara, CA, USA) was used for visualization according to the
manufacturer’s instructions. Three different lobular areas were
analyzed in each sample and images were captured using a
Nikon Eclipse E400 optical microscope (Nikon) and the NIS
Elements Imaging Software (Melville). Intensity of CD36 stain
was quantified using the FIJI software (NIH) and reported as the
average value in arbitrary units (a.u.).
Statistical Analysis
Categorical variables were presented as percentage and were
compared by the Pearson χ2 test. Continuous data were shown
as standard deviation (SD) or standard error of mean (SEM),
and were compared using the unpaired t-test or Mann-Whitney
U-test, as indicated. The Spearman’s r-test was used to evaluate
correlations. All statistical analyses were performed using the
GraphPad Prism 6 software (GraphPad Software Inc., San Diego,
CA, USA) and SPSS statistical software version 24.0 (IBM
SPSS Statistics, Armonk, NY), with a p < 0.05 considered
statistically significant.
RESULTS
Characteristics of the Study Patients
Twenty patients undergoing programmed cholecystectomy had
both a liver biopsy and a sleep study. Overall, the mean age
of the study population was 46.5 years, 14 (70%) were female
and 9 (45%) had a diagnosis of OSA by polygraphy (AHI > 5).
Patient characteristics from the cohort included in this study are
presented in Table 1.
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TABLE 1 | Demographic, metabolic, biochemical, respiratory, and histological








Age (years) 39.9 ± 9.6 54.6 ± 10.6 0.004
BMI (kg/m2 ) 26.5 ± 6.7 28.6 ± 5.1 0.201
Waist circunference (cm) 91.8 ± 14.4 105.5 ± 11.6 0.034
Glucose (mg/dL) 92.2 ± 9.3 96.2 ± 11.9 0.359
Insulin (µU/L) 7.2 ± 2.9 9.2 ± 4.5 0.245
HOMA-IR 1.6 ± 0.7 2.1 ± 1 0.192
Triglycerides (mg/dL) 111.2 ± 54.2 136.4 ± 68.9 0.467
Total Cholesterol (mg/dL) 207 ± 32.3 210 ± 29.5 0.832
HDL-cholesterol (mg/dL) 53.5 ± 12.8 46.9 ± 9.5 0.212
ALT (IU/L) 24.6 ± 17.4 27.2 ± 19.3 0.489
AST (IU/L) 22.1 ± 9.3 21.3 ± 5.6 0.808
γGT (IU/L) 33.4 ± 24.4 28.4 ± 14.5 0.601
Alkaline phosphatase (IU/L) 70.3 ± 22.7 61 ± 13.6 0.359
Bilirubin (mg/dL) 0.7 ± 0.36 0.63 ± 0.32 0.780
Average oxygen saturation
(%)
94 ± 1.7 93.3 ± 1.4 0.225
Minimum oxygen saturation
(%)
88.2 ± 4.2 83.7 ± 5.9 0.073
AHI (events/hour) 0.9 ± 1 10 ± 9.2 0.002
ODI (events/hour) 0.6± 0.6 9.2 ± 9.5 <0.001








Grade 0 63.6% 22.2%
Grade 1 27.3% 22.2%
Grade 2 9.1% 44.5%
Grade 3 11.1%
Lobular Inflammation (%)
Grade 0 91% 77.8%
Grade 1 9% 22.2%
Grade 2
Ballooning (%)




Stage 0 100% 100%
Data are shown as mean ± standard deviation.
OSA, obstructive sleep apnea; BMI, body mass index; HOMA-IR, homeostatic
model assessment-insulin resistance; HDL, high density lipoprotein; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; γGT, gamma-
glutamiltranspeptidase; AHI, apnea-hipopnea index; ODI, oxygen desatutaion
index; Tc90, sleep time with oxygen saturation <90%.
OSA patients were significantly older than those without OSA
(p = 0.004) and women predominated in both groups. In order
to evaluate the presence of obesity in the entire study population,
body mass index (BMI) was calculated and waist circumference
was measured in each participant. Regarding BMI, the study
population showed an overweight status and no significant
differences were found among the different patient groups
studied (p = 0.201), whereas waist perimeter was significantly
higher in patients with OSA than in those without (p= 0.034).
As expected, OSA patients had a significantly higher rate of
oxygen desaturation per hour of sleep (ODI) and percentage of
sleep time with oxygen saturations lower than 90% (Tc90) with
respect to patients without OSA (Table 1).
Regarding metabolic parameters, basal glucose levels did not
significantly differ between groups, while insulin levels and the
degree of insulin resistance assessed by HOMA-IR index were
higher in OSA patients than in those without OSA, but these
differences were not statistically significant (Table 1).
Although no significant differences were observed in liver
enzymes between the two groups, there was a higher prevalence
of NAFLD and evidence of more severe disease among patients
with OSA (Table 1 and Figure 1A). Surprisingly, 36.4% of
patients without OSA exhibited NAFLD, all of them featuring
simple steatosis. In the OSA group, however, 55.6% of them
had simple steatosis and 22.2% showed histological features of
steatohepatitis (NASH) (Table 1 and Figure 1A). Hepatic fibrosis
was not observed. All other variables did not significantly differ
between groups.
Expression of CD36 Is Increased Within the
Liver of OSA Patients
Next, we wanted to investigate whether OSA might alter CD36
expression in the liver. Interestingly, hepatic mRNA levels of
CD36 were significantly higher in patients with OSA when
compared with control patients (Figure 1B), and its expression
significant positively correlated with both AHI and ODI values
in the entire study population (Figure 1C), but not with Tc90
(Supplementary Figure 1A). In parallel, an increase of CD36
protein expression was also observed in the livers from OSA
patients compared with those from the control group detected
by immunostaining (Figure 1D).
Intermittent Hypoxia (IH) Triggers Hepatic
Steatosis in Mice
In order to investigate whether intermittent hypoxia (IH), one of
the main features of OSA, contributes to liver steatosis and to the
increase of CD36 expression observed in OSA patients, a mouse
experimental model of OSA was used. After 2 months of IH
exposure, histological examinations of liver tissue revealed that
60% of the mice submitted to IH exhibited signs of mild hepatic
steatosis while control mice displayed normal liver features
(Figures 2A,B). Liver fibrosis was not detected in any of the
groups (Supplementary Figure 2).
Next, we investigated the amount of lipids performing an
Oil Red O staining on sections of liver biopsy samples from
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FIGURE 1 | Prevalence of NAFLD and hepatic CD36 expression is higher in patients diagnosed with OSA. (A) NAFLD activity score. (B) CD36 mRNA levels. (C)
Correlation in the study population of matched mRNA values for CD36 with the indicated respiratory parameters, evaluated by Spearman’s r-test. (D) Representative
20X and 60X images of CD36 immunostaining, and quantification of CD36-expressing cells. Scale bar 100 and 50µm, respectively. Study population: control group
(No-OSA) (n = 11) and OSA patients (n = 9). *p < 0.05, OSA vs. Control, compared using the Mann-Whitney U-test.
all mice. The results indicated that there was a significant
increase in average red-stain intensity (directly proportional
to lipid content) among the IH mice when compared to
control mice (Figure 2C). To further evaluate hepatic lipid
content, triglycerides were extracted and quantified from liver
biopsies of both IH and C mice. Triglyceride levels of
the IH mice were greater than those observed in the C
mice (Figure 2D).
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FIGURE 2 | Intermittent Hypoxia (IH) is associated with increased hepatic lipid content in mice. (A) Representative 20X and 60X images of liver sections stained with
hematoxylin and eosin (H&E). Scale bar 100 and 50µm, respectively. (B) NAFLD activity score. (C) (left panel) Representative 40X and 60X images of Oil Red O
stained liver sections. Scale bar 50µm. (right panel) Quantification of red-stain intensity. (D) Analysis of hepatic triglyceride (TG) levels. Experimental groups: mice
maintained in normoxic conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (n = 10 mice in each group). **p < 0.01 and ***p < 0.005, IH vs. C,
compared using the unpaired t-test.
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FIGURE 3 | Intermittent Hypoxia (IH) induces hepatic CD36 expression in mice. (A) mRNA levels of Fasn, Scd1, Cpt1a, and Ppara. (B) Cd36 mRNA levels. (C) (left
panel) Representative blots with the indicated antibodies. (right panel) Quantification of all blots with respect to loading control, βactin. (D) (left panel) Representative
20X and 60X images from CD36 immunochemistry. Scale bar 100 and 50µm, respectively. (right panel) Quantification of CD36-stain intensity. Experimental groups:
mice maintained in normoxic conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (n = 10 mice in each group). *p < 0.05 and ***p < 0.005, IH vs. C,
compared using the unpaired t-test.
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Intermittent Hypoxia (IH) Induces Hepatic
CD36 Expression
tHEN, we analyzed the hepatic expression of genes involved in
the regulation of lipid metabolism. We observed a significant
increase in the expression of genes implicated in lipid synthesis,
such as Fasn (fatty acid synthase) and Scd1 (stearoyl-CoA
desaturase 1), among livers frommice exposed to IH (Figure 3A);
however, no differences were observed in the expression of
genes implicated in β-oxidation, such as Cpt1a (carnitine
palmitoyltransferase I) and Ppara (peroxisome proliferator
activated receptor alpha) (Figure 3A).
With respect to CD36, its hepatic mRNA expression was
significantly increased in mice submitted to IH compared to
those maintained in normoxic conditions (Figure 3B), which
was also found in OSA patients. In parallel, its protein
expression determined by both Western blot (Figure 3C) and
immunohistochemistry (Figure 3D) was elevated in the livers of
IH mice.
DISCUSSION
Distinct clinical studies have reported that OSA is significantly
associated with NAFLD severity (26) and there is an increasing
experimental evidence that chronic IH, the best characterized
OSA manifestation, is a major trigger for oxidative stress and
inflammatory liver injury leading to NAFLD progression (17).
In agreement with these previous studies, we found that 22.2%
of OSA patients had NASH whereas none of those without OSA
had histological features of NASH, supporting the assumption
that OSA is a risk factor for progression from simple steatosis to
NASH (27). Interestingly, our findings showed that there were
no differences regarding BMI between the two study groups,
but waist circumference was significantly higher in patients
with OSA, suggesting that is abdominal obesity, but not overall
obesity, what actually has a clinical impact on the features of
metabolic syndrome, including OSA and NAFLD.
To the best of our knowledge, this is the first study revealing
that CD36 expression is significantly elevated in livers from
patients with OSA. Moreover, both AHI and ODI positively
correlated with hepaticCD36mRNA levels, indicating a potential
role for nocturnal IH in the upregulation of this FFA transporter.
An intriguing question regarding our findings showed herein is
whether agemight influence the hepatic CD36 expression pattern
observed in OSA patients because they were significantly older
(54.6 ± 10.6 years) than those without OSA (39.9 ± 9.6 years).
Indeed, we have reported that hepatic CD36 expression increased
with aging in mice and humans (13), but the age-dependent
increases in hepatic CD36 expression were observed comparing
young (20–38 years old) with aged individuals (50–83 years), thus
we believe that age differences seen in our study population are
not sufficient to explain the hepatic CD36 upregulation observed
in OSA patients. Supporting this assumption, no correlation was
found between CD36 mRNA expression and age in our study
population (Supplementary Figure 1B).
In agreement with our findings in OSA patients, the majority
of mice exposed to IH displayed simple steatosis as well as a
higher hepatic TG content and CD36 expression than in control
mice breathing normal oxygen concentrations. Collectively, our
results indicate that IH may contribute to hepatosteatosis setup,
partly by the upregulation of hepatic CD36 expression, but the
underlying molecular mechanisms still remain to be elucidated.
It is well-known that cellular adaptive responses to hypoxia
are tightly regulated by hypoxia-inducible transcription factors
(HIFs), being HIF1α and HIF2α the best characterized (28).
In that regard, Li et al. demonstrated that IH exacerbated
hepatosteatosis in mice in parallel with an upregulation of
key genes for hepatic lipid biosynthesis, such as Srebp1 and
Scd1 (20) and that this effect is mediated through HIF1α
(29). In line with these results, our study also found increased
mRNA levels of relevant genes for de novo lipogenesis, such
as Fasn and Scd1, along with an upregulation of Cd36 gene
expression in livers of mice exposed to IH, suggesting that
HIF1α might regulate Cd36 gene expression as well. There is
convincing evidence, however, indicating that the regulation of
CD36 expression is not largely linked to the HIF1α/SREBP1c
signaling pathway in hepatocytes. Notably, it has been recently
reported that hepatocyte-specific Srebp1 downregulation did not
affect expression of genes involved in FFA uptake as Cd36 in
mouse livers (30). In addition, we have just demonstrated that
both CD36 expression and triglyceride content increased in
mouse and human liver cells under hypoxic conditions and that
silencing HIF2A gene markedly suppressed both CD36 gene
upregulation and lipid accumulation in hepatocytes (14). The
novelty of our present study is that both CD36 expression and
the degree of steatosis are increased in livers from animal models
of IH and in patients with OSA featured by nocturnal IH,
supporting the notion that CD36 could be a key factor driving
hepatosteatosis in OSA patients.
In conclusion, the results of the present study demonstrate
that CD36 expression is increased within the liver of patients with
OSA and in mice exposed to IH, the clinical hallmark featuring
OSA. Moreover, our results point out that the excessive lipid
accumulation observed in livers of mice under IH conditions
is likely due to the upregulation of CD36, which is involved
in FFA uptake into hepatocytes, along with that of genes
implicated in de novo lipogenesis, thus leading to the onset of
hepatosteatosis, the earliest phase of NAFLD. Collectively, our
findings shed light on the molecular mechanisms underlying IH-
induced hepatosteatosis helping to understand better the NAFLD
pathogenesis and identifying CD36 as a potential target for new
pharmacological therapies to NAFLD patients.
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Study population: control group (No-OSA) (n = 11) and OSA patients (n = 9).
Supplementary Figure 2 | Representative images of liver sections stained with
Masson’s trichrome solution. Experimental groups: mice raised in normoxic
conditions (Control, C) and mice exposed to intermittent hypoxia (IH) (n = 10 mice
in each group).
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